IN VITRO ANTIBIOTIC SYNERGY COLISTIN-RESISTANT KLEBSIELLA PNEUMONIAE

Colistin-resistant Klebsiella pneumoniae (coRKP) infections can cause problems with management, increasing risk for morbidity and mortality but it is unclear which antibiotic combinations are most effective in their treatment. In this study we aimed to determine the activity of individual antibiotic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Southeast Asian journal of tropical medicine and public health 2019-07, Vol.50 (4), p.703-707
Hauptverfasser: Prawang, Abhisit, Santimaleeworagun, Wichai, Changpradub, Dhitiwat, Thunyaharn, Sudaluck, Puttilerpong, Chankit
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 707
container_issue 4
container_start_page 703
container_title Southeast Asian journal of tropical medicine and public health
container_volume 50
creator Prawang, Abhisit
Santimaleeworagun, Wichai
Changpradub, Dhitiwat
Thunyaharn, Sudaluck
Puttilerpong, Chankit
description Colistin-resistant Klebsiella pneumoniae (coRKP) infections can cause problems with management, increasing risk for morbidity and mortality but it is unclear which antibiotic combinations are most effective in their treatment. In this study we aimed to determine the activity of individual antibiotics and combinations of antibiotics against coRKP using minimum inhibitory concentrations (MICs) of individual antibiotics and the checkerboard technique, respectively. We used the broth microdilution technique to determine the MIC values for tigecycline, gentamicin, amikacin, fosfomycin, chloramphenicol, meropenem, imipenem, ciprofloxacin and colistin against coRKP. The studied coRKP isolates were obtained from patients treated at Phramongkutklao Hospital in Bangkok, Thailand during January 2016-December 2018. None of the isolates tested were susceptible to meropenem, imipenem, ciprofloxacin or colistin but all the isolates were susceptible to tigecycline, amikacin and gentamicin. During in vitro checkerboard testing, a synergistic effect was seen for the following combinations: fosfomycin plus gentamicin seen in 30% of isolates, fosfomycin plus tigecycline seen in 30% of isolates and tigecycline plus gentamicin seen in 13 % of isolates. In vivo studies are needed to determine if these combinations result in a significantly different outcome than treatment using individual antibiotics. To summarize, there were varying sensitivity to tested antibiotics among tested isolates. The combinations of fosfomycin plus gentamicin and fosfomycin plus tigecycline should be explored further for possible combination therapy of coRKP at the studied institution.
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2535570741</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2535570741</sourcerecordid><originalsourceid>FETCH-LOGICAL-p183t-49a89c4f07c3ef7d8ba9a572b863b37c11a74c7eb83f728564be6f93dacb423f3</originalsourceid><addsrcrecordid>eNotjctOAyEARVloYq3-A4nrSXgOsJyOWIkIZoaadNUAhUVjbO20_-8kurpncXLuDVggTHiDeUvuwP00HRBiCCu5AM_GwU8TBg87F8zK-GB6OG6dHtZb2HtrxmBcM-hxhtmAb1avRqOt7eCH05t370ynH8BtjV9TefzfJdi86NC_NtavTd_Z5oQlvTRMRakyq0hkWqrYyxRV5IIk2dJERcY4CpZFSZJWQSRvWSptVXQfc2KEVroET3_d0_n4cy3TZXc4Xs_f8-WOcMq5QIJh-gsqgT_i</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2535570741</pqid></control><display><type>article</type><title>IN VITRO ANTIBIOTIC SYNERGY COLISTIN-RESISTANT KLEBSIELLA PNEUMONIAE</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Prawang, Abhisit ; Santimaleeworagun, Wichai ; Changpradub, Dhitiwat ; Thunyaharn, Sudaluck ; Puttilerpong, Chankit</creator><creatorcontrib>Prawang, Abhisit ; Santimaleeworagun, Wichai ; Changpradub, Dhitiwat ; Thunyaharn, Sudaluck ; Puttilerpong, Chankit</creatorcontrib><description>Colistin-resistant Klebsiella pneumoniae (coRKP) infections can cause problems with management, increasing risk for morbidity and mortality but it is unclear which antibiotic combinations are most effective in their treatment. In this study we aimed to determine the activity of individual antibiotics and combinations of antibiotics against coRKP using minimum inhibitory concentrations (MICs) of individual antibiotics and the checkerboard technique, respectively. We used the broth microdilution technique to determine the MIC values for tigecycline, gentamicin, amikacin, fosfomycin, chloramphenicol, meropenem, imipenem, ciprofloxacin and colistin against coRKP. The studied coRKP isolates were obtained from patients treated at Phramongkutklao Hospital in Bangkok, Thailand during January 2016-December 2018. None of the isolates tested were susceptible to meropenem, imipenem, ciprofloxacin or colistin but all the isolates were susceptible to tigecycline, amikacin and gentamicin. During in vitro checkerboard testing, a synergistic effect was seen for the following combinations: fosfomycin plus gentamicin seen in 30% of isolates, fosfomycin plus tigecycline seen in 30% of isolates and tigecycline plus gentamicin seen in 13 % of isolates. In vivo studies are needed to determine if these combinations result in a significantly different outcome than treatment using individual antibiotics. To summarize, there were varying sensitivity to tested antibiotics among tested isolates. The combinations of fosfomycin plus gentamicin and fosfomycin plus tigecycline should be explored further for possible combination therapy of coRKP at the studied institution.</description><identifier>ISSN: 0125-1562</identifier><language>eng</language><publisher>Bangkok: Central Coordinating Board, SEAMEO-TROPMED Project</publisher><subject>Amikacin ; Antibiotics ; Chloramphenicol ; Chloromycetin ; Ciprofloxacin ; Colistin ; Fosfomycin ; Gentamicin ; Imipenem ; In vivo methods and tests ; Klebsiella ; Meropenem ; Minimum inhibitory concentration ; Morbidity ; Synergistic effect ; Tigecycline</subject><ispartof>Southeast Asian journal of tropical medicine and public health, 2019-07, Vol.50 (4), p.703-707</ispartof><rights>Copyright Central Coordinating Board, SEAMEO-TROPMED Project Jul 2019</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Prawang, Abhisit</creatorcontrib><creatorcontrib>Santimaleeworagun, Wichai</creatorcontrib><creatorcontrib>Changpradub, Dhitiwat</creatorcontrib><creatorcontrib>Thunyaharn, Sudaluck</creatorcontrib><creatorcontrib>Puttilerpong, Chankit</creatorcontrib><title>IN VITRO ANTIBIOTIC SYNERGY COLISTIN-RESISTANT KLEBSIELLA PNEUMONIAE</title><title>Southeast Asian journal of tropical medicine and public health</title><description>Colistin-resistant Klebsiella pneumoniae (coRKP) infections can cause problems with management, increasing risk for morbidity and mortality but it is unclear which antibiotic combinations are most effective in their treatment. In this study we aimed to determine the activity of individual antibiotics and combinations of antibiotics against coRKP using minimum inhibitory concentrations (MICs) of individual antibiotics and the checkerboard technique, respectively. We used the broth microdilution technique to determine the MIC values for tigecycline, gentamicin, amikacin, fosfomycin, chloramphenicol, meropenem, imipenem, ciprofloxacin and colistin against coRKP. The studied coRKP isolates were obtained from patients treated at Phramongkutklao Hospital in Bangkok, Thailand during January 2016-December 2018. None of the isolates tested were susceptible to meropenem, imipenem, ciprofloxacin or colistin but all the isolates were susceptible to tigecycline, amikacin and gentamicin. During in vitro checkerboard testing, a synergistic effect was seen for the following combinations: fosfomycin plus gentamicin seen in 30% of isolates, fosfomycin plus tigecycline seen in 30% of isolates and tigecycline plus gentamicin seen in 13 % of isolates. In vivo studies are needed to determine if these combinations result in a significantly different outcome than treatment using individual antibiotics. To summarize, there were varying sensitivity to tested antibiotics among tested isolates. The combinations of fosfomycin plus gentamicin and fosfomycin plus tigecycline should be explored further for possible combination therapy of coRKP at the studied institution.</description><subject>Amikacin</subject><subject>Antibiotics</subject><subject>Chloramphenicol</subject><subject>Chloromycetin</subject><subject>Ciprofloxacin</subject><subject>Colistin</subject><subject>Fosfomycin</subject><subject>Gentamicin</subject><subject>Imipenem</subject><subject>In vivo methods and tests</subject><subject>Klebsiella</subject><subject>Meropenem</subject><subject>Minimum inhibitory concentration</subject><subject>Morbidity</subject><subject>Synergistic effect</subject><subject>Tigecycline</subject><issn>0125-1562</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNotjctOAyEARVloYq3-A4nrSXgOsJyOWIkIZoaadNUAhUVjbO20_-8kurpncXLuDVggTHiDeUvuwP00HRBiCCu5AM_GwU8TBg87F8zK-GB6OG6dHtZb2HtrxmBcM-hxhtmAb1avRqOt7eCH05t370ynH8BtjV9TefzfJdi86NC_NtavTd_Z5oQlvTRMRakyq0hkWqrYyxRV5IIk2dJERcY4CpZFSZJWQSRvWSptVXQfc2KEVroET3_d0_n4cy3TZXc4Xs_f8-WOcMq5QIJh-gsqgT_i</recordid><startdate>20190701</startdate><enddate>20190701</enddate><creator>Prawang, Abhisit</creator><creator>Santimaleeworagun, Wichai</creator><creator>Changpradub, Dhitiwat</creator><creator>Thunyaharn, Sudaluck</creator><creator>Puttilerpong, Chankit</creator><general>Central Coordinating Board, SEAMEO-TROPMED Project</general><scope>3V.</scope><scope>7QL</scope><scope>7SS</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BVBZV</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>P64</scope><scope>PATMY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PYCSY</scope></search><sort><creationdate>20190701</creationdate><title>IN VITRO ANTIBIOTIC SYNERGY COLISTIN-RESISTANT KLEBSIELLA PNEUMONIAE</title><author>Prawang, Abhisit ; Santimaleeworagun, Wichai ; Changpradub, Dhitiwat ; Thunyaharn, Sudaluck ; Puttilerpong, Chankit</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p183t-49a89c4f07c3ef7d8ba9a572b863b37c11a74c7eb83f728564be6f93dacb423f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Amikacin</topic><topic>Antibiotics</topic><topic>Chloramphenicol</topic><topic>Chloromycetin</topic><topic>Ciprofloxacin</topic><topic>Colistin</topic><topic>Fosfomycin</topic><topic>Gentamicin</topic><topic>Imipenem</topic><topic>In vivo methods and tests</topic><topic>Klebsiella</topic><topic>Meropenem</topic><topic>Minimum inhibitory concentration</topic><topic>Morbidity</topic><topic>Synergistic effect</topic><topic>Tigecycline</topic><toplevel>online_resources</toplevel><creatorcontrib>Prawang, Abhisit</creatorcontrib><creatorcontrib>Santimaleeworagun, Wichai</creatorcontrib><creatorcontrib>Changpradub, Dhitiwat</creatorcontrib><creatorcontrib>Thunyaharn, Sudaluck</creatorcontrib><creatorcontrib>Puttilerpong, Chankit</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>East &amp; South Asia Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Environmental Science Collection</collection><jtitle>Southeast Asian journal of tropical medicine and public health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Prawang, Abhisit</au><au>Santimaleeworagun, Wichai</au><au>Changpradub, Dhitiwat</au><au>Thunyaharn, Sudaluck</au><au>Puttilerpong, Chankit</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>IN VITRO ANTIBIOTIC SYNERGY COLISTIN-RESISTANT KLEBSIELLA PNEUMONIAE</atitle><jtitle>Southeast Asian journal of tropical medicine and public health</jtitle><date>2019-07-01</date><risdate>2019</risdate><volume>50</volume><issue>4</issue><spage>703</spage><epage>707</epage><pages>703-707</pages><issn>0125-1562</issn><abstract>Colistin-resistant Klebsiella pneumoniae (coRKP) infections can cause problems with management, increasing risk for morbidity and mortality but it is unclear which antibiotic combinations are most effective in their treatment. In this study we aimed to determine the activity of individual antibiotics and combinations of antibiotics against coRKP using minimum inhibitory concentrations (MICs) of individual antibiotics and the checkerboard technique, respectively. We used the broth microdilution technique to determine the MIC values for tigecycline, gentamicin, amikacin, fosfomycin, chloramphenicol, meropenem, imipenem, ciprofloxacin and colistin against coRKP. The studied coRKP isolates were obtained from patients treated at Phramongkutklao Hospital in Bangkok, Thailand during January 2016-December 2018. None of the isolates tested were susceptible to meropenem, imipenem, ciprofloxacin or colistin but all the isolates were susceptible to tigecycline, amikacin and gentamicin. During in vitro checkerboard testing, a synergistic effect was seen for the following combinations: fosfomycin plus gentamicin seen in 30% of isolates, fosfomycin plus tigecycline seen in 30% of isolates and tigecycline plus gentamicin seen in 13 % of isolates. In vivo studies are needed to determine if these combinations result in a significantly different outcome than treatment using individual antibiotics. To summarize, there were varying sensitivity to tested antibiotics among tested isolates. The combinations of fosfomycin plus gentamicin and fosfomycin plus tigecycline should be explored further for possible combination therapy of coRKP at the studied institution.</abstract><cop>Bangkok</cop><pub>Central Coordinating Board, SEAMEO-TROPMED Project</pub><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0125-1562
ispartof Southeast Asian journal of tropical medicine and public health, 2019-07, Vol.50 (4), p.703-707
issn 0125-1562
language eng
recordid cdi_proquest_journals_2535570741
source EZB-FREE-00999 freely available EZB journals
subjects Amikacin
Antibiotics
Chloramphenicol
Chloromycetin
Ciprofloxacin
Colistin
Fosfomycin
Gentamicin
Imipenem
In vivo methods and tests
Klebsiella
Meropenem
Minimum inhibitory concentration
Morbidity
Synergistic effect
Tigecycline
title IN VITRO ANTIBIOTIC SYNERGY COLISTIN-RESISTANT KLEBSIELLA PNEUMONIAE
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T09%3A34%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=IN%20VITRO%20ANTIBIOTIC%20SYNERGY%20COLISTIN-RESISTANT%20KLEBSIELLA%20PNEUMONIAE&rft.jtitle=Southeast%20Asian%20journal%20of%20tropical%20medicine%20and%20public%20health&rft.au=Prawang,%20Abhisit&rft.date=2019-07-01&rft.volume=50&rft.issue=4&rft.spage=703&rft.epage=707&rft.pages=703-707&rft.issn=0125-1562&rft_id=info:doi/&rft_dat=%3Cproquest%3E2535570741%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2535570741&rft_id=info:pmid/&rfr_iscdi=true